Intellia Therapeutics (NTLA) closed at $11.21 on October 23, 2026, up 0.4% from the previous close, on volume of 3,130,681 shares (30-day average 5,093,522).
Data as of October 23, 2026.
23-Oct-2026
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer
Globe Newswire (Tue, 13-Oct 7:30 AM ET)
Intellia uses inducement RSUs to add eight new hires under Nasdaq Rule 5635(c)(4)
Market Chameleon (Mon, 5-Oct 3:31 AM ET)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 2-Oct 4:01 PM ET)
Globe Newswire (Tue, 8-Sep 8:00 AM ET)
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
Globe Newswire (Fri, 4-Sep 8:50 AM ET)
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Globe Newswire (Fri, 4-Sep 8:00 AM ET)
Intellia's Positive Phase 3 Data and Strong Cash Position Highlight Road to 2027 Launch
Market Chameleon (Thu, 6-Aug 3:20 AM ET)
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Globe Newswire (Thu, 6-Aug 7:00 AM ET)
Intellia Therapeutics Sets August 6 Call for Q2 2026 Results and Strategic Business Updates
Market Chameleon (Thu, 30-Jul 4:05 AM ET)
Globe Newswire (Thu, 30-Jul 8:00 AM ET)
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Intellia Therapeutics trades on the NASDAQ stock market under the symbol NTLA.
As of October 23, 2026, NTLA stock price climbed to $11.21 with 3,130,681 million shares trading.
NTLA has a beta of 2.03, meaning it tends to be more sensitive to market movements. NTLA has a correlation of 0.06 to the broad based SPY ETF.
NTLA has a market cap of $1.57 billion. This is considered a Small Cap stock.
Last quarter Intellia Therapeutics reported $8 million in Revenue and -$.80 earnings per share. This fell short of revenue expectation by $-6 million and met earnings estimates .
In the last 3 years, NTLA traded as high as $34.87 and as low as $5.90.
The top ETF exchange traded funds that NTLA belongs to (by Net Assets): ARKE, ARKK, XBI, VTI, IWM.
NTLA has underperformed the market in the last year with a price return of -56.7% while the SPY ETF gained +14.3%. NTLA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +1.0% and -14.2%, respectively, while the SPY returned +3.2% and -2.4%, respectively.
NTLA support price is $10.68 and resistance is $11.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NTLA shares will trade within this expected range on the day.